证券代码：301370 证券简称：国科恒泰 公告编号：2025-066 国科恒泰（北京）医疗科技股份有限公司 第三届董事会第四十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）第三届 董事会第四十五次会议已于 2025 年 10 月 20 日通过电子邮件方式通知了全体董 事。 2、本次会议于 2025 年 10 月 27 日以现场与通讯相结合的方式召开。 4、本次董事会会议的召集、召开和表决程序符合《中华人民共和国公司法》 等法律、法规及《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 经与会董事认真审议，充分讨论，审慎表决，会议审议通过了以下议案： 1、审议通过《关于<2025 年第三季度报告>的议案》 公司根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所创业板 上市公司自律监管指南第 2 号——公告格式：第 46 号上市公司季度报告公告格 式》等相关规定编制了《2025 年第三季度报告》。 公司《2025 年第三季度报告》的具体内容详见公 ...

Financial Performance - The company's revenue for Q3 2025 was ¥1,674,554,353.82, representing a decrease of 8.02% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2025 was ¥15,261,028.68, down 58.58% year-on-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥10,298,811.06, a decline of 70.64% compared to the previous year[11]. - The basic and diluted earnings per share for Q3 2025 were both ¥0.03, reflecting a decrease of 66.67% from ¥0.09 in Q3 2024[9]. - Total operating revenue for the current period is ¥5,353,226,595.70, a decrease of 2.3% from ¥5,479,472,836.38 in the previous period[21]. - Net profit for the current period is ¥73,266,609.62, a decline of 26.9% compared to ¥100,187,565.39 in the previous period[23]. - Earnings per share for the current period is ¥0.14, down from ¥0.21 in the previous period[23]. Cash Flow and Liquidity - The net cash flow from operating activities for the first nine months of 2025 was ¥490,326,618.41, down 30.65% from ¥707,063,637.76 in the same period last year[10]. - Cash generated from operating activities is ¥6,140,694,388.48, a decrease from ¥6,376,867,755.75 in the previous period[24]. - Net cash flow from operating activities was $490.33 million, a decrease of 30.7% compared to $707.06 million in the previous period[25]. - Total cash inflow from operating activities was $7.89 billion, while cash outflow was $7.40 billion, resulting in a net increase of $490.33 million[25]. - The ending balance of cash and cash equivalents was $714.35 million, down from $868.64 million in the previous period[26]. - Cash received from tax refunds amounted to $1.75 billion, compared to $1.58 billion previously[25]. - Cash paid for employee compensation was $170.42 million, a slight decrease from $177.90 million in the previous period[25]. - Cash paid for taxes was $104.93 million, down from $128.26 million in the previous period[25]. Assets and Liabilities - Total assets at the end of Q3 2025 were ¥6,319,891,150.33, a decrease of 4.77% from the end of the previous year[5]. - The total assets of the company as of September 30, 2025, amounted to CNY 6,319,891,150.33, a decrease from CNY 6,636,569,329.88 at the beginning of the period[17]. - Current assets decreased from CNY 5,849,378,587.75 to CNY 5,505,997,878.68, reflecting a decline of approximately 5.86%[17]. - The company's total liabilities decreased from CNY 4,636,569,329.88 to CNY 4,319,891,150.33, reflecting a decrease of about 6.84%[17]. - Total liabilities amount to ¥3,760,412,120.93, down from ¥4,073,989,164.42 in the previous period[22]. - Total equity stands at ¥2,559,479,029.40, slightly down from ¥2,562,580,165.46 in the previous period[22]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,223[13]. - The largest shareholder, Dongfang Keyi Holdings, holds a 30.13% stake in the company[13]. - The equity attributable to shareholders at the end of Q3 2025 was ¥2,506,344,685.30, an increase of 1.19% from the previous year[5]. Operational Metrics - The company reported a significant decline in gross profit, which contributed to the decrease in net profit[9]. - Total operating costs for the current period are ¥5,254,415,583.98, down 1.9% from ¥5,354,912,218.48 in the previous period[22]. - The company reported a significant increase in other income to ¥6,683,689.24 from ¥1,687,365.75 in the previous period[22]. - The company experienced a rise in financial expenses, totaling ¥28,328,643.67 compared to ¥50,041,270.06 in the previous period[22]. - The company’s deferred income tax liabilities increased to ¥5,961,518.99 from ¥2,580,903.48 in the previous period[22]. Inventory and Receivables - Accounts receivable decreased from CNY 1,558,930,002.18 to CNY 1,492,181,605.80, a reduction of approximately 4.26%[18]. - Inventory decreased from CNY 2,708,459,897.69 to CNY 2,488,669,913.27, indicating a decline of about 8.11%[18]. - The company reported a significant increase in other receivables, which rose from CNY 188,086,486.40 to CNY 156,290,622.07, a decrease of approximately 16.91%[18]. Fixed and Non-Current Assets - The company's fixed assets decreased slightly from CNY 539,150,113.33 to CNY 519,220,711.92, a decline of about 3.70%[18]. - The company’s non-current assets increased from CNY 787,190,742.13 to CNY 813,893,271.65, reflecting an increase of approximately 3.41%[18]. Audit Status - The company’s third-quarter financial report was not audited[27].

Core Points - Guoke Hengtai (301370) reported that as of October 20, 2025, the number of shareholders is 17,405 [1]

Market Overview - The medical consumables supply chain SPD sector increased by 0.41% compared to the previous trading day, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Jianfa Zhixin (301584) closed at 29.30, up 4.46% with a trading volume of 186,400 shares and a transaction value of 534 million [1] - Dajia Weikang (301126) closed at 11.75, up 3.07% with a trading volume of 53,500 shares and a transaction value of 62.22 million [1] - Jianmo Information (605186) closed at 19.55, up 2.68% with a trading volume of 17,200 shares and a transaction value of 33.43 million [1] - Other notable performers include Hefei China (603122) up 1.91%, Langma Information (300288) up 1.48%, and Seli Medical (603716) up 1.48% [1] Capital Flow - The SPD sector experienced a net outflow of 43.97 million from institutional investors, while retail investors saw a net inflow of 16.33 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Seli Medical (603716) had a net inflow of 12.83 million from institutional investors, but a net outflow of 12.61 million from speculative funds [3] - Dajia Weikang (301126) saw a net inflow of 5.24 million from speculative funds, but a net outflow of 5.91 million from retail investors [3] - Huadong Pharmaceutical (000963) had a net inflow of 2.37 million from speculative funds, while retail investors experienced a net outflow of 4.64 million [3]

证券代码：301370 证券简称：国科恒泰 公告编号：2025-064 关于为下属子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国科恒泰（北京）医疗科技股份有限公司 特别风险提示： 国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）对资产负债率 超过 70%的单位预计担保金额超过公司最近一期经审计净资产的 50%，前述担保 均为对公司合并报表范围内子公司的担保，财务风险处于公司可控范围内，提请投 资者充分关注担保风险。 一、担保情况概述 根据公司经营发展需要，公司于 2025 年第二次临时股东大会审议通过《关于 对外担保额度预计的议案》，同意公司向合并报表范围内子公司提供担保额度总额 为 18.55 亿元。其中，为资产负债率 70%以上的合并报表范围内子公司提供担保的 额度为 14.15 亿元；为资产负债率低于 70%的合并报表范围内子公司提供担保的额 度为 4.40 亿元。 上述额度按实际生效的金额（签订担保合同且额度有效期间内存续的担保）进 行总额控制，在担保额度总额范围内，公司子公司间可进行担保额度调剂，但调剂 发生时资 ...

国科恒泰（北京）医疗科技股份有限公司 企业负责人经营业绩考核管理办法 第一章 总则 （三）坚持依法依规。准确把握出资人监管边界，依法合规履行出资人职权， 坚持以管资本为主加强国有资产监管，有效落实国有资产保值增值责任。 （四）坚持短期目标与长远发展有机统一。切实发挥企业战略引领作用，构 建立足当前、着眼长远的考核体系。 （五）坚持行业对标。瞄准行业先进水平，强化行业对标，不断提升企业在 所在产业发展中的话语权和影响力，加快成为具有行业竞争力的一流企业。 （六）坚持业绩考核与激励约束紧密结合。坚持权责利相统一，建立与企业 负责人选任方式相匹配、与企业功能性质相适应、与经营业绩相挂钩的差异化激 励约束机制。 第一条 为切实履行国有资产出资人职责，维护股东权益，落实国有资产保 值增值责任，建立有效的激励约束机制，根据《中华人民共和国企业国有资产法》 《企业国有资产监督管理暂行条例》等有关法律法规，以及国家及中国科学院控 股有限公司（以下简称国科控股）、东方科仪控股集团有限公司（以下简称东方 科仪控股）相关文件精神，全面落实加强国有企业经营业绩考核管理相关要求， 结合公司实际情况，制定本办法。 第二条 本办法适用于国 ...

国科恒泰（北京）医疗科技股份有限公司 企业负责人薪酬管理办法 第一章 总则 第一条 为推动国科恒泰（北京）医疗科技股份有限公司（以下简称国科恒 泰或公司）进一步建立健全企业负责人员激励约束机制，根据国家及中国科学院 控股有限公司（以下简称国科控股）、东方科仪控股集团有限公司（以下简称东 方科仪控股）相关文件精神，全面落实加强国有企业薪酬管理相关要求，结合公 司实际情况，制定本办法。 第二条 本办法适用于公司的党支部书记、副书记，董事长、总经理、副总 经理、财务总监（财务负责人）、董事会秘书，以及公司章程规定的其他对企业 发展具有重大决定权、负有重要责任的人员，下文均以"企业负责人"代指。 第三条 薪酬管理遵循下列原则： （一）坚持战略引领。聚焦企业使命愿景，强化战略导向，构建面向助力战 略有效实施的企业负责人薪酬体系。 （二）坚持目标导向。聚焦企业发展目标，突出价值贡献，强化目标绑定， 构建适应企业发展的企业负责人薪酬确定机制。 （三）坚持分类管理。聚焦企业差异管控，强化分类施策，构建与企业使命 定位相适应的企业负责人薪酬管理制度。 （六）强化统筹兼顾。兼顾公平性和市场竞争力，优化企业负责人与职工之 间的收入 ...

证券代码：301370 证券简称：国科恒泰 公告编号：2025-063 国科恒泰（北京）医疗科技股份有限公司 关于召开 2025 年第四次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2025年第四次临时股东大会 2、股东大会的召集人：董事会 3、会议召开的合法、合规性：本次股东大会召集程序、召开符合有关法律、行政 法规、部门规章、规范性文件和《公司章程》的规定。 4、会议时间： （1）现场会议时间：2025年10月31日14:30 （2）网络投票时间： 通过深圳证券交易所系统进行网络投票的具体时间为2025年10月31日9:15-9:25， 9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为2025 年10月31日9:15至15:00的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 （1）现场投票：股东本人出席本次现场会议或者通过授权委托书委托他人出席现 场会议；（2）网络投票：本次股东大会通过深圳证券交易所交易系统和互联网投票系 统（ht ...

国科恒泰（北京）医疗科技股份有限公司 第三届董事会第四十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）第三届 董事会第四十四次会议已于 2025 年 9 月 29 日通过电子邮件方式通知了全体董事。 2、本次会议于 2025 年 10 月 15 日以现场与通讯相结合的方式召开。 3、会议由公司董事长刘冰先生召集并主持，会议应出席董事 9 名，实际出 席董事 9 名（其中董事刘冰、肖薇以现场方式参加会议，其他董事以通讯方式参 加会议）。公司监事及高级管理人员列席了本次会议。 4、本次董事会会议的召集、召开和表决程序符合《中华人民共和国公司法》 等法律、法规及《公司章程》的有关规定，合法有效。 证券代码：301370 证券简称：国科恒泰 公告编号：2025-062 为建立有效的激励约束机制，全面落实加强国有企业经营业绩考核管理相关 要求，公司根据有关法律法规及相关工作要求，结合实际情况，制定了《企业负 责人经营业绩考核管理办法》。 该议案具体内容详见公司于 20 ...

Group 1 - The core viewpoint of the news is that Guoke Hengtai's stock performance and financing activities indicate a low level of financing compared to its market value, while its short-selling activities are at a high level [1][2]. Group 2 - Guoke Hengtai (Beijing) Medical Technology Co., Ltd. was established on February 7, 2013, and went public on July 12, 2023. The company specializes in the distribution and direct sales of medical devices, providing services such as warehousing, logistics, channel management, and hospital SPD operation management [2]. - The main revenue composition of Guoke Hengtai includes vascular interventional treatment materials (71.09%), other products (14.58%), non-vascular interventional treatment materials (5.27%), orthopedic materials (5.12%), oral materials (2.25%), neurosurgical materials (1.08%), and others (0.59%) [2]. - As of September 19, the number of shareholders of Guoke Hengtai was 17,700, an increase of 0.33% from the previous period, with an average of 18,332 circulating shares per person, a decrease of 0.33% [2]. - For the first half of 2025, Guoke Hengtai achieved operating revenue of 3.679 billion yuan, a year-on-year increase of 0.54%, while the net profit attributable to the parent company was 52.0954 million yuan, a year-on-year decrease of 17.20% [2]. - Since its A-share listing, Guoke Hengtai has distributed a total of 94.3268 million yuan in dividends [3].